Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:00:38 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Six killed in a 'foiled coup' in Congo, the army says
Next:Election 2024: Biden and Trump bypassed the Commission on Presidential Debates
You may also like
- Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
- Framber Valdez pitches 7 strong innings and Astros use a late 4
- 700 union workers launch 48
- Emotional Mbappé confirms he will leave PSG ahead of an expected move to Real Madrid
- US overdose deaths dropped in 2023, the first time since 2018
- Meghan and Harry take Nigeria by storm as they pose for fun selfies
- I'm an American living in the UK... here's why universal healthcare is not all roses
- Woman sentenced to 55 years for death of longtime friend stabbed nearly 500 times
- Company wins court ruling to continue development of Michigan factory serving EV industry